Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $8.00, but opened at $6.88. Oxford BioMedica shares last traded at $6.88, with a volume of 1,000 shares traded.
Analysts Set New Price Targets
Separately, Zacks Research upgraded shares of Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of “Hold”.
Read Our Latest Stock Report on Oxford BioMedica
Oxford BioMedica Stock Down 6.3%
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Recommended Stories
- Five stocks we like better than Oxford BioMedica
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
